RayKnowChina Research Map
Shortlist

RecruitingCoronary heart diseasePhase 4

Registered title, quoted from ClinicalTrials.gov

Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction

An open trial on coronary heart disease, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 41 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 41

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Hospital of Changchun University of Chinese Medicine长春中医药大学附属医院ChangchunHospital page
  2. Study siteAffiliated Hospital of Guizhou Medical University贵州医科大学附属医院GuiyangHospital page
  3. Study siteAffiliated Hospital of Qingdao University青岛大学附属医院QingdaoHospital page
  4. Study siteAffiliated Hospital of Shandong University of Traditional Chinese Medicine山东中医药大学附属医院JinanHospital page
  5. Study siteBeijing Hospital北京医院BeijingHospital page
  6. Study siteDaqing Oilfield General HospitalDaqingHospital page
  7. Study siteDongfang Hospital北京中医药大学东方医院BeijingHospital page
  8. Study siteEighth Affiliated Hospital of Sun Yat-sen University中山大学附属第八医院ShenzhenHospital page
  9. Study siteFifth Affiliated Hospital of Sun Yat-sen University中山大学附属第五医院ZhuhaiHospital page
  10. Study siteFirst Affiliated Hospital of Dalian Medical University大连医科大学附属第一医院DalianHospital page
  11. Study siteFirst Affiliated Hospital of Guangxi Medical University广西医科大学第一附属医院NanningHospital page
  12. Study siteFirst Affiliated Hospital of Harbin Medical University哈尔滨医科大学附属第一医院HarbinHospital page
  13. Study siteFirst Affiliated Hospital of Hebei North University河北北方学院附属第一医院ZhangjiakouHospital page
  14. Study siteFirst Affiliated Hospital of Sun Yat-sen University中山大学附属第一医院GuangzhouHospital page
  15. Study siteFirst Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page
  16. Study siteFirst Hospital of China Medical University中国医科大学附属第一医院ShenyangHospital page
  17. Study siteFirst Hospital of Jilin University吉林大学第一医院ChangchunHospital page
  18. Study siteFirst Hospital of Lanzhou University兰州大学第一医院LanzhouHospital page
  19. Study siteGeneral Hospital of Ningxia Medical University宁夏医科大学总医院YinchuanHospital page
  20. Study siteGuang'anmen Hospital中国中医科学院广安门医院BeijingHospital page
  21. Study siteHangzhou First People's Hospital杭州市第一人民医院HangzhouHospital page
  22. Study siteHebei General Hospital河北省人民医院ShijiazhuangHospital page
  23. Study siteHuzhou Central Hospital湖州市中心医院HuzhouHospital page
  24. Study siteNingbo Medical Center Lihuili Hospital宁波市医疗中心李惠利医院NingboHospital page
  25. Study sitePeople's Hospital of Guangxi Zhuang Autonomous Region广西壮族自治区人民医院NanningHospital page
  26. Study siteQilu Hospital of Shandong University山东大学齐鲁医院JinanHospital page
  27. Study siteRuijin Hospital上海交通大学医学院附属瑞金医院ShanghaiHospital page
  28. Study siteSecond Affiliated Hospital of Harbin Medical University哈尔滨医科大学附属第二医院HarbinHospital page
  29. Study siteSecond Affiliated Hospital of Xi'an Jiaotong University西安交通大学第二附属医院Xi'anHospital page
  30. Study siteSecond Hospital of Jilin University吉林大学第二医院ChangchunHospital page
  31. Study siteSecond Hospital of Tianjin Medical University天津医科大学第二医院TianjinHospital page
  32. Study siteShanghai Tenth People's Hospital上海市第十人民医院ShanghaiHospital page
  33. Study siteShantou University Medical College hospitals汕头大学医学院附属医院ShantouHospital page
  34. Study siteSichuan Provincial People's Hospital四川省人民医院ChengduHospital page
  35. Study siteSir Run Run Shaw Hospital浙江大学医学院附属邵逸夫医院HangzhouHospital page
  36. Study siteSouthwest Hospital, Army Medical University陆军军医大学第一附属医院(西南医院)ChongqingHospital page
  37. Study siteTianjin Chest Hospital天津市胸科医院TianjinHospital page
  38. Study siteXinhua Hospital上海交通大学医学院附属新华医院ShanghaiHospital page
  39. Study siteYantai Yuhuangding Hospital烟台毓璜顶医院YantaiHospital page
  40. Study siteZhejiang Provincial People's Hospital浙江省人民医院HangzhouHospital page
  41. Study siteZhongda Hospital, Southeast University东南大学附属中大医院NanjingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07110415, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 3

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (3 points)Hide the checklist
  1. 40 years to 80 years; sex: all

    Registered eligibility fields

  2. Patients with malignant tumors and other pathological conditions with an expected survival of less than 3 years;

    Exclusion criterion 11

  3. Pregnant or lactating women, or those planning pregnancy during the study period;

    Exclusion criterion 6

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07110415, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • For inpatients diagnosed with coronary heart disease (including acute coronary syndrome and chronic coronary syndrome), it is up to the doctor to decide whether to undergo revascularization and what kind of revascularization to use.
  • Patients aged between 40 and 80 years (inclusive), regardless of sex;
  • Patients with NYHA cardiac function classes II-IV;
  • Patients with NT-proBNP > 125 pg/mL (or BNP>35 pg/mL);
  • The syndrome differentiation in traditional Chinese medicine conforms to chest obstruction (qi deficiency and blood stasis syndrome)
  • Patients who voluntarily participated and signed an informed consent form.

Exclusion Criteria:

  • Patients with STEMI within 3 days;
  • Patients at extremely high risk of NSTEMI (hemodynamic instability, cardiogenic shock, new-onset heart failure or aggravated heart failure, severe ventricular arrhythmia)
  • Patients with acute myocardial infarction complicated with cardiogenic shock, mechanical complications, respiratory failure and other multiple organ failure;
  • Patients with severe liver dysfunction (transaminase levels more than three times the upper limit of normal), renal insufficiency (eGFR < 30mL/min/1.73m2), acute infectious diseases, and mental disorders;以上翻译结果来自有道神经网络翻译(YNMT)· 通用场景
  • Patients with drug-resistant hypertension (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg);
  • Pregnant or lactating women, or those planning pregnancy during the study period;
  • Patients who cannot tolerate 3 months of dual antiplatelet therapy;
  • Patients with allergic reactions or abnormal drug reactions to the study drug or any of its excipients;
  • Patients who have regularly taken Yangxinshi tablets and similar traditional Chinese medicine, Chinese patent medicine or traditional Chinese medicine decoction with the same curative effectin the past month;
  • Patients who have participated in other clinical drug trials within the last three months;
  • Patients with malignant tumors and other pathological conditions with an expected survival of less than 3 years;
  • Patients whom the investigator deems unsuitable for participating in the clinical trial.

Quoted from ClinicalTrials.gov, NCT07110415, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07110415, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07110415